Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1220 results
September 2023
-
Media Release
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from… -
Media Release
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced… -
Media Release
Novartis confirms Sandoz Spin-off for October 4, 2023
Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023Sandoz to be included in key Swiss market indicesInvestment grade… -
Media Release
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half… -
Media Release
Novartis shareholders approve the proposed 100% Spin-off of Sandoz
Shareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off… -
Media Release
Les actionnaires de Novartis approuvent le projet de scission à 100% de Sandoz
Les actionnaires approuvent le projet de scission à 100% de Sandoz, l’activité Génériques et Biosimilaires de NovartisLes actionnaires approuvent également une réduction du capital social dans le… -
Media Release
Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.Die Aktionärinnen und Aktionäre stimmen ausserdem einer… -
Media Release
Novartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
Patient-reported outcomes (PROs) from the Phase III NATALEE trial show that patients receiving adjuvant Kisqali plus endocrine therapy (ET) for up to three years maintained physical and social… -
Media Release
Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering
Agreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North AmericaUstekinumab is a fully human monoclonal antibody to… -
Media Release
Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis
After nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of Novartis Dr. Horber to drive next phase… -
Media Release
Novartis ernennt Dr. Patrick Horber zum President, International, da Marie-France Tschudin, President, Innovative Medicines International und Chief Commercial Officer, aus der Geschäftsleitung von Novartis ausscheidet
Nach fast sieben Jahren bei Novartis und mehr als vier Jahren als Mitglied der Geschäftsleitung wird Marie-France Tschudin ihr nächstes Führungskapitel ausserhalb von Novartis beginnen Dr. Horber… -
Media Release
Novartis nomme Patrick Horber, Docteur en médecine, au poste de President, International, alors que Marie-France Tschudin, President, Innovative Medicines International et Chief Commercial Officer, quitte le Comité exécutif de Novartis
Après près de sept années chez Novartis et plus de quatre années en tant que membre du Comité exécutif de Novartis, Mme Tschudin poursuivra sa carrière de leader en dehors de Novartis Le Dr Horber…